Published in Pain and Central Nervous System Week, September 17th, 2007
This Phase III study is a double-blind randomised placebo-controlled study of Sativex(R) in patients with central neuropathic pain due to MS, who have achieved inadequate pain relief with existing therapies. The study has recruited 339 patients in the UK, Canada, France, Spain and the Czech Republic and is GW's largest clinical trial to date.
The duration of treatment in the study is 14 weeks. The last patient will exit the study at the end of 2007 with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week